» Articles » PMID: 17293865

High-throughput Oncogene Mutation Profiling in Human Cancer

Abstract

Systematic efforts are underway to decipher the genetic changes associated with tumor initiation and progression. However, widespread clinical application of this information is hampered by an inability to identify critical genetic events across the spectrum of human tumors with adequate sensitivity and scalability. Here, we have adapted high-throughput genotyping to query 238 known oncogene mutations across 1,000 human tumor samples. This approach established robust mutation distributions spanning 17 cancer types. Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation. Moreover, we identified previously unrecognized oncogene mutations in several tumor types and observed an unexpectedly high number of co-occurring mutations. These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention.

Citing Articles

Evaluation of the Ki-67 labeling index on immediate pre-ablation biopsies as a predictive biomarker of local recurrence of colorectal cancer liver metastases.

Sotirchos V, Vakiani E, Sigel C, Imam R, Kunin H, Cooke T Cytotechnology. 2025; 77(1):31.

PMID: 39744311 PMC: 11685365. DOI: 10.1007/s10616-024-00700-8.


Clinical bioinformatics desiderata for molecular tumor boards.

Pallocca M, Betti M, Baldinelli S, Palombo R, Bucci G, Mazzarella L Brief Bioinform. 2024; 25(5).

PMID: 39297878 PMC: 11411775. DOI: 10.1093/bib/bbae447.


Rapid but nondurable response of a exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors.

Sinichenkova K, Sidorov I, Kriventsova N, Konovalov D, Abasov R, Usman N Oncotarget. 2024; 15:493-500.

PMID: 39018206 PMC: 11254299. DOI: 10.18632/oncotarget.28606.


Genetic Variability of CYP4F2, CYP2D6, CYP2E1, and ACE in the Chinese Yi Population.

Guo J, Zhou W, Ma X, Li Y, Zhang H, Wei J Biochem Genet. 2024; .

PMID: 38850376 DOI: 10.1007/s10528-024-10748-y.


MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon.

Monga J, Ghosh R, Guddeti R, Chitale D, Khan G, Ghosh J Front Oncol. 2024; 14:1387535.

PMID: 38746674 PMC: 11091401. DOI: 10.3389/fonc.2024.1387535.